FDA To Conduct Inspections Focusing on 21 CFR 11 Requirements Relating to Human Drugs

More News:

• 02/09/2012 Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com

  The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.

• 02/09/2012 FDA Issues Draft Guidance on Biosimilar Product Development

  The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.

• 02/08/2012 Biomedical Industry Loses Momentum in California, According to 2012 Report

  Innovation slows as productivity in the Biomedical industry declines

• 02/02/2012 Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com

  About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.

• 02/02/2012 News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com

  Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.

• 02/01/2012 Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com

  Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.

• 01/26/2012 News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com

  Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.

• 01/24/2012 ISPE Announces 2012 FOYA Winners
• 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
• 01/19/2012 Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com

  Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.

• All news »